3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Neoplasm Metastasis
8
Esophageal Neoplasms
8
Carcinoma, Hepatocellular
7
Melanoma
6
Lung Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
4
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Nasopharyngeal Carcinoma
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Breast Neoplasms, Male
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms
1
Pleural Mesothelial Neoplasm
1
Interventions
Cisplatin
3
Radiotherapy, Intensity-Modulated
2
pembrolizumab
1
palbociclib
1
durvalumab
1
Taxes
1
Pemetrexed
1
Paclitaxel
1
Nimorazole
1
Immunotherapy
1
Cell Count
1
Carboplatin
1
Bevacizumab
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
Immunotherapy
×
1 year
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled